Currently, therapeutic strategies for advanced NSCLC with no driver gene mutations have turned to immunotherapy, such as immune checkpoint inhibitors (ICIs) that target the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) axis or CTLA-4. The gene discussed is CD274; the disease is non-small cell lung carcinoma.